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INTRODUCTION
The American Diabetes Association has recommended that the levels of glycated hemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes be maintained at \7%
(53 mmol/mol) and \100 mg/dL, respectively [1] ; however, a majority of patients with diabetes do not have these parameters under control, either individually or in combination [2] .
HbA1c control has been shown to be associated with a reduced risk of microvascular complications in the general population of patients with diabetes [3] [4] [5] but the evidence is mixed with regards to cardiovascular benefits.
Some studies have observed cardiovascular benefits of HbA1c control in relatively less severe patients with diabetes [6] [7] [8] or those newly diagnosed with or screened for diabetes [8] [9] [10] ; however, a recent study on the impact of early use of insulin treatment to normalize glucose levels found no difference in cardiovascular benefits compared with standard treatment [11] . In addition, cardiovascular benefits of LDL-C control in diabetes have been well documented [12] [13] [14] [15] [16] . An intensive, multifactorial intervention approach in type 2 diabetes patients, designed to simultaneously target HbA1c, cholesterol levels, and other risk factors, has been shown to significantly reduce the risk of cardiovascular morbidity and mortality, microvascular complications, and rates of cardiovascular surgery [17, 18] .
The benefits of achieving both HbA1c and LDL-C goals, compared with achieving just one, have not been quantified among newly diagnosed type 2 diabetes patients.
Cardiovascular disease is the most frequent cause of death in patients with diabetes [19] . While some studies suggest that tight glycemic control reduces cardiovascular risk in patients who are newly diagnosed with diabetes [9] , it is unclear whether achieving the HbA1c goal in addition to the LDL-C goal will have additional cardiovascular benefits. The primary objective 
METHODS

Data Source
Electronic medical records from the South Central Veterans Affairs Health Care Network, 
Data Preparation
Longitudinal data were analyzed according to 6-month cycles, starting from the index date. Average HbA1c and LDL-C levels were estimated for each cycle using the area under the curve method [20, 21] . For each cycle, the following estimated averages were used to group patients into one of four goal achievement categories: dual-goal [HbA1c \7% (53 mmol/mol) and LDL-C \100 mg/dL], HbA1c only [HbA1c \7% (53 mmol/mol) and LDL-C C100 mg/dL], LDL-C only [LDL-C \100 mg/dL and HbA1c C7%
(53 mmol/mol)], or neither goal [HbA1c C7% (53 mmol/mol) and LDL-C C100 mg/dL].
Patient Characteristics
Patient characteristics during the first 6-month cycle were summarized for the overall sample as well as stratified by goal achievement status. 
Characteristics Associated with Dual-Goal Achievement
To identify characteristics associated with dual-goal achievement 7-12 months after the index date, a logistic regression model was used to assess the effects of individual factors. These include demographics, dual-goal achievement within 6 months following the index date, and complications and comorbidities, diabetic medication use, surgical procedures, resource utilization (i.e., outpatient, inpatient, and ER visits), the Charlson Comorbidity Index (CCI, a validated measure of the overall health status) [22] within the 1-year period surrounding the index date (i.e., 6 months before and 6 months after the index date). The likelihood of achieving both goals relative to not achieving both goals was quantified using adjusted odds ratios (ORs) with 95% CIs. SAS software version 9.2 (Cary, NC, USA) was used to conduct statistical analyses, and a two-tailed a level of 0.05 was used to determine statistical significance.
RESULTS
Patient Characteristics
A total of 16,829 newly diagnosed patients were included in the analysis (Fig. 1 .001
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All characteristics were measured in the first 6-month cycle HbA1c glycosylated hemoglobin A1c, LDL-C low-density lipoprotein cholesterol a Dual-goal achievement was defined as HbA1c \7%
(53 mmol/mol) and LDL-C \100 mg/dL; LDL-C goal achievement, LDL-C\100 mg/dL and HbA1c C7%
(53 mmol/mol); HbA1c goal achievement, HbA1c\7% (53 mmol/mol) and LDL-C C100 mg/dL; no goal achievement, HbA1c C7%
(53 mmol/mol) and LDL-C C100 Table 2 ).
DISCUSSION
The results from this study show that the achievement of both HbA1c and LDL-C goals in patients with newly diagnosed type 2 diabetes is associated with an additional reduction of microvascular complication rates, group [24] . However, in Steno-2, a randomized study in patients with established diabetes (mean disease duration: 6 years), multifactorial treatment was associated with significantly lower rates of cardiovascular disease and microvascular complications after 7.8 years of follow-up, compared with standard care [17] , and further 5.5 years of follow-up demonstrated significant benefits on cardiovascular mortality [18] . In both periods of the Steno-2 study, multifactorial treatment resulted in a higher proportion of patients who achieved HbA1c levels \6.5% (48 mmol/mol) and in mean LDL-C levels \100 mg/dL [17, 18] . Taken together, data from our analysis and the studies that assessed the effects of multifactorial intervention [17, 18, 24] suggest that cardiovascular benefits of dual-goal over single-goal achievements in patients with type 2 diabetes may be observed over a long term. [18] .
The observed cardiovascular benefits of single-goal achievement (HbA1c or LDL-C) versus no-goal achievement are also consistent with literature [25] [26] [27] .
Status and Characteristics Associated with Dual-Goal Achievement
Given that, only 44.2% of patients achieved both the HbA1c and LDL-C goals in the 7-12 month period following the index date, our results suggest an unmet need in controlling major risk factors for patients with newly diagnosed diabetes. This is consistent with available literature [2] .
Our results also show that prior dual-goal (53 mmol/mol) were generally older and less likely to receive insulin than patients who had not achieved HbA1c goal [30] . The Look AHEAD study (ClinicalTrials.gov # NCT00017953) suggested that insulin use and non-utilization of lipid-lowering drugs was associated with a failure to achieve all three goals (HbA1c, LDL-C, and blood pressure) among overweight and obese patients with diabetes [31] . Finally, achievement of the LDL-C goal has been directly associated with older age, and inversely associated with baseline LDL-C [32] .
Limitations and Strengths
Due to the retrospective observational design, the analysis may have been affected by unobserved differences that were not taken into account in the model. Although we used strict selection criteria, there is a possibility we included some patients who were not truly newly diagnosed with T2DM. Specifically, we observed an unexpectedly high rate of insulin use during the 6-month post-index period.
Patients who did not achieve either goal were on average about 8 years younger and used 4 times more insulin than those who achieved both goals (20.9% vs. 5.0%). It is possible that some of these younger patients who were using insulin were suffering from latent autoimmune diabetes of adults instead of type 2 diabetes [33] .
In addition, some important information was not captured in the electronic medical records, including disease severity, disease duration, lifestyle modifications, and any potential (but unlikely) health care services that were provided outside of the Veterans Affairs (VA) health system. We did not look into the specific information about alternative cholesterol-lowering drugs and antihypertensive drugs. Furthermore, the VA database predominantly consists of male patients, which may limit generalization of findings. One of the major advantages of using electronic records from VA health system is that the lab values are recorded over time, allowing for a longitudinal study design with a median follow-up period of 3.7 years.
Similar studies in the general population, designed to assess the effects of medication, lifestyle changes, or triple-goal achievement (HbA1c, LDL-C, and blood pressure) may provide additional information. In addition, analyses with longer follow-up times may reveal benefits of dual-or triple-goal achievements on cardiovascular outcomes that were not observed in this study.
CONCLUSION
In US veterans with a newly recorded diagnosis of type 2 diabetes, the main benefit of achieving both HbA1c and LDL-C goals over achieving only LDL-C goal appears to be a reduced rate of microvascular complications. However, current rates of dual-goal achievement are suboptimal. Prior dual-goal achievement and use of lipid-lowering drugs were both associated with a higher rate of dual-goal achievement, which highlights the importance of early intervention and regular medical care.
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